This study was supported by grants from Science and Technology Committee of Jiangsu and Health Bureau of Jiangsu. Objective To evaluate the characteristics of P glycoprotein(P gp) expression of acute non lym...This study was supported by grants from Science and Technology Committee of Jiangsu and Health Bureau of Jiangsu. Objective To evaluate the characteristics of P glycoprotein(P gp) expression of acute non lymphocytic leukemia (ANLL) at different status and the prognostic and biological features in ANLL at diagnosis. Methods Monoclonal antibody UIC2 and indirect immunofluorescence assay by flow cytometry were used to determine P gp expression of 169 patients with ANLL, including 152 previously untreated, 7 refractory and 10 at remission. Results P gp was expressed in 28.9% of the previously untreated ANLL cases and P gp was lower than that in 71.4% of the refractory cases (P<0.05). No P gp expression was found in the patients at remission. For previously untreated ANLL, P gp was highly expressed in hybrid acute leukemia (66.7%) and acute monoblastic leukemia (47.4%). P gp expression was highly associated with surface markers [cluster of differentiation (CD) 34, CD7, CD14, CD42b and CD61] and unfavorable cytogenetic abnormalities. About 23% of P gp +ANLL obtained complete remission, which was significantly lower than that (76%) in P gp - cases. Conclusions P gp expression is higher in refractory ANLL cases than that in cases at diagnosis or at remission. P gp is an index of poor prognosis in adults with ANLL. P gp +ANLL cases have unique clinical and biological characteristics.展开更多
文摘This study was supported by grants from Science and Technology Committee of Jiangsu and Health Bureau of Jiangsu. Objective To evaluate the characteristics of P glycoprotein(P gp) expression of acute non lymphocytic leukemia (ANLL) at different status and the prognostic and biological features in ANLL at diagnosis. Methods Monoclonal antibody UIC2 and indirect immunofluorescence assay by flow cytometry were used to determine P gp expression of 169 patients with ANLL, including 152 previously untreated, 7 refractory and 10 at remission. Results P gp was expressed in 28.9% of the previously untreated ANLL cases and P gp was lower than that in 71.4% of the refractory cases (P<0.05). No P gp expression was found in the patients at remission. For previously untreated ANLL, P gp was highly expressed in hybrid acute leukemia (66.7%) and acute monoblastic leukemia (47.4%). P gp expression was highly associated with surface markers [cluster of differentiation (CD) 34, CD7, CD14, CD42b and CD61] and unfavorable cytogenetic abnormalities. About 23% of P gp +ANLL obtained complete remission, which was significantly lower than that (76%) in P gp - cases. Conclusions P gp expression is higher in refractory ANLL cases than that in cases at diagnosis or at remission. P gp is an index of poor prognosis in adults with ANLL. P gp +ANLL cases have unique clinical and biological characteristics.
